Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice

British Journal of Pharmacology

Volumn 173, Issue 4, 2016, Pages 752-765

  Krishnan, S M ^a   Dowling, J K ^b   Ling, Y H ^a   Diep, H ^a   Chan, C T ^a   Ferens, D ^a   Kett, M M ^a   Pinar, A ^b   Samuel, C S ^a   Vinh, A ^a   Arumugam, T V ^c,d   Hewitson, T D ^e   Kemp Harper, B K ^a   Robertson, A A B ^f   Cooper, M A ^f   Latz, E ^g,h,i   Mansell, A ^b   Sobey, C G ^a   Drummond, G R ^a  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Sungkyunkwan University   (South Korea)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h UNIVERSITY OF MASSACHUSETTS   (United States)

ⁱ GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; COLLAGEN; CRYOPYRIN; DEOXYCORTICOSTERONE ACETATE; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MCC 950; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; APOPTOSIS REGULATORY PROTEIN; DEOXYCORTICOSTERONE; INORGANIC SALT; PYCARD PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASC GENE; BIOACCUMULATION; CASPASE 1 GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; GENE; GENE EXPRESSION REGULATION; HYPERTENSION; IL 1BETA GENE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY FIBROSIS; MACROPHAGE; MALE; MOUSE; NLRP3 GENE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; KIDNEY DISEASE; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; DESOXYCORTICOSTERONE; HYPERTENSION; INFLAMMASOMES; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SALTS;

EID: 84957437207     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13230     Document Type: Article

References (65)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol 170: 1676-1705.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
3. Aoi W, Niisato N, Sawabe Y, Miyazaki H, Tokuda S, Nishio K, et al. (2007). Abnormal expression of ENaC and SGK1 mRNA induced by dietary sodium in Dahl salt-sensitively hypertensive rats. Cell Biol Int 31: 1288-1291.
4. Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, et al. (2015). Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press 24: 7-13.
5. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V, (2011). Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 187: 613-617.
6. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. (2009). Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183: 787-791.
7. Bautista L, Vera L, Arenas I, Gamarra G, (2005). Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 19: 149-154.
8. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC, (2001). Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37 (2 Pt 2): 781-786.
9. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG, (2003). Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791-1800.
10. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, (2006). Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 37: 1503-1507.
11. Cahill CM, Rogers JT, (2008). Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 283: 25900-25912.
12. Chan C, Moore J, Budzyn K, Guida E, Diep H, Vinh A, et al. (2012). Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension 60: 1207-1212.
13. Chantong B, Kratschmar DV, Nashev LG, Balazs Z, Odermatt A, (2012). Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells. J Neuroinflammation 9: 260: e1-14.
14. Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, et al. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21: 248-255.
15. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC, (1997). Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med 129: 300-308.
16. Dinarello CA, (1996). Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
17. Dinarello CA, (1999). Interleukin-18. Methods 19: 121-132.
18. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361.
19. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM, (2008). TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76-R83.
20. Feig DI, Soletsky B, Johnson RJ, (2008). Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300: 924-932.
21. Haig A, (1889). On uric acid and arterial tension. Br Med J 1: 288-291.
22. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865.
23. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. (2011). Inflammation, immunity, and hypertension. Hypertension 57: 132-140.
24. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
25. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. (1995). Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151: 1628-1631.
26. Kahlenberg JM, Lundberg KC, Kertesy SB, Qu Y, Dubyak GR, (2005). Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol 175: 7611-7622.
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
28. Krege JH, Hodgin JB, Hagaman JR, Smithies O, (1995). A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115.
29. Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR, (2014). IL-1beta and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol 171: 5589-5602.
30. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH, (2011). Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 186: 5738-5748.
31. Latz E, (2010). The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 22: 28-33.
32. Lee C, Chun J, Hwang SW, Kang SJ, Im JP, Kim JS, (2014). Enalapril inhibits nuclear factor-kappaB signaling in intestinal epithelial cells and peritoneal macrophages and attenuates experimental colitis in mice. Life Sci 95: 29-39.
33. Lee D, Sturgis L, Labazi H, Osborne J, Fleming C, Pollock J, et al. (2006). Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290: H935-H940.
34. Madhur M, Lob H, McCann L, Iwakura Y, Blinder Y, Guzik T, et al. (2010). Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55: 500-507.
35. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, et al. (2009). Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740-F748.
36. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. (2004). Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430: 213-218.
37. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
38. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J, (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
39. Mattson DL, (2014). Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am J Physiol Renal Physiol 307: F499-F508.
40. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. (2001). Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106.
41. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
42. Meng F, Yamagiwa Y, Ueno Y, Patel T, (2006). Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 44: 1055-1065.
43. Mertens M, Singh JA, (2009). Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36: 1118-1125.
44. Mezzano SA, Ruiz-Ortega M, Egido J, (2001). Angiotensin II and renal fibrosis. Hypertension 38 (3 Pt 2): 635-638.
45. Mills K, Dungan L, Jones S, Harris J, (2013). The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 93: 489-497.
46. Moore JP, Sakkal S, Bullen ML, Kemp-Harper BK, Ricardo SD, Sobey CG, et al. (2013). A flow cytometric method for the analysis of macrophages in the vascular wall. J Immunol Methods 396: 33-43.
47. Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, et al. (2011). Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol 186: 6119-6128.
48. Omi T, Kumada M, Kamesaki T, Okuda H, Munkhtulga L, Yanagisawa Y, et al. (2006). An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur J Hum Genet 14: 1295-1305.
49. Ozaki E, Campbell M, Doyle SL, (2015). Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J Inflamm Res 8: 15-27.
50. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
51. Rabkin SW, (2009). The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med 6: 192-199.
52. Ridker PM, Thuren T, Zalewski A, Libby P, (2011). Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162: 597-605.
53. Rodriguez-Iturbe B, Johnson RJ, (2010). The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res 33: 975-980.
54. Rodriguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ, (2012). Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol 39: 96-103.
55. Schlesinger N, (2014). Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep 16: 398.
56. Schmittgen TD, Livak KJ, (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
57. Schroder K, Tschopp J, (2010a). The inflammasomes. Cell 140: 821-832.
58. Schroder K, Zhou R, Tschopp J, (2010b). The NLRP3 inflammasome: a sensor for metabolic danger? Science 327: 296-300.
59. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH, (2009). Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31: 331-341.
60. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, et al. (2002). Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2: 3.
61. Wang AQ, So A, Nussberger J, Ives A, Bagnoudi N, Shaefer S, et al. (2014). Renin-dependent hypertension in mice requires the NLRP3-inflammasome. J Hypertens 3: e1-6.
62. Wei Z, Spizzo I, Diep H, Drummond GR, Widdop RE, Vinh A, (2014). Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice. PLoS ONE 9: e114895.
63. Wen H, Ting J, O'Neill L, (2012). A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol 13: 352-357.
64. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, Jones P, et al. (1994). Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 91: 742-746.
65. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, et al. (2012). Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 59: 136-144.